首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
The European Commission said on Thursday it would toughen the regulation of medical devices as a result of concerns raised by br
The European Commission said on Thursday it would toughen the regulation of medical devices as a result of concerns raised by br
admin
2011-02-03
27
问题
The European Commission said on Thursday it would toughen the regulation of medical devices as a result of concerns raised by breast implants produced by the defunct French company PIP, even as a scientific expert review it ordered concluded there was currently "insufficient evidence" that women using its products faced greater health risks than others.
John Dalli, health and consumer policy commissioner, pledged to examine surveillance and operation of the "notified bodies" that scrutinise medical devices across the EU in a current review of legislation, stressing: "The capacity to detect and minimise the risk of fraud must be increased."
His comments followed an official report released on Wednesday in France that called for national and EU-wide co-operation including random inspections and sampling of medical devices to prevent a repeat of the fraudulent use of substandard non-medical-grade silicone by PIP in implants sold to up to 400,000 women around the world.
Xavier Bertrand, France’s minister of health, called for enhanced action in France and across Europe in the wake of the study, which highlighted that Afssaps, the French medical regulator, did not inspect PIP from 2001 until a tip-off led officials to inspect and close down the company in 2010. Jean-Claude Mas, its founder, is under police investigation for manslaughter.
Mr. Bertrand has pledged to hire more health inspectors and undertake random checks on medical device companies following growing concerns over its regulatory system highlighted by the widespread use of PIP’s substandard breast implants.
A French decision at the end of last year to offer all women free removal of PIP implants triggered similar proposals in the UK, Germany and the Czech Republic and has helped spark a fresh debate over tougher EU regulation of medical devices, which are subject to far less scrutiny than pharmaceuticals.
However, a review released on Thursday by the EU’s own Scientific Committee on Emerging and Newly Identified Health Risks concluded: "Breast implants can fail, regardless of manufacturer, and the probability of failure increases with time since implantation. In most cases, breast implant failure appears to be without identifiable health consequences for the patient with the exception of possible local complications."
It stressed that limited data meant that while there was no link between breast implants and cancer, there was a need for further work to understand the specific risks from the PIP products.
Mr. Bertrand has endorsed calls for a parliamentary inquiry in France as well as a report from the country’s social affairs inspectorate, mirroring similar moves that led to tough new requirements for the pharmaceutical industry introduced last year in the wake of concerns about Servier’s drug Mediator.
Medical device manufacturers have called for reforms to ensure that the national "notified bodies" which audit the quality of their products across Europe are of a consistently high standard, while cautioning that tough new regulatory requirements could harm the EU’s competitive advantage.
The French study showed that Afssaps had received multiple warnings over the relatively high failure rate of PIP implants compared with those made by other companies, even though the overall proportion remained modest.
From Financial Times, February 2, 2012
Which of the following statements is true according to the passage?
选项
A、There is a consensus on the EU regulation of medical devices in the European Union.
B、All breast implant failure appears to be without identifiable health consequences.
C、Tough new regulatory requirements could harm the EU’s competitive advantage.
D、The overall proportion of the implant failure is relatively high compared with others.
答案
C
解析
本题为概括题。根据第六段“spark a fresh debate over tougher EU regulation of medical devices”可知A错误;根据第七段“breast implant failure appears to be without identifiable health consequences for the patient with the exception of possible local complications”可知B错误;根据倒数第二段“while cautioning that tough new regulatory requirements could harm the EU’s competitive advantage”可知C正确;根据最后一段“even though the overall proportion remained modest”可知D错误。
转载请注明原文地址:https://kaotiyun.com/show/cM1K777K
0
专业英语四级
相关试题推荐
MysisterhasbeentoseveralAfricancountriesaswellasallofEuropethisyear.Bythetimeshe’sthirty,she______almostev
Betweenthetworoads______aTVtowercalled"SkyscrapedTower".
Somememberssuggested______apartyforthevisitor,buttheChairmandidn’tapprove.
Morepeoplewilleatoutinrestaurants______theydotoday.
Mostpeopleexperiencecomputersas"end-users"ofpackagedprograms.Unfortunatelythewritersoftheseprogramscan’tknowthe
Thegreatestrecentsocialchangeshavebeen【C1】______thelivesofwomen.Duringthe20thcenturytherehasbeenaremarkable
Whenyouchooseafreezer,rememberit’sprobablygoingtobewithyouforalongtime.Nosinglestyleorsizeisbest,soit’s
ThemandidthefollowingthroughtheInternetthatdayEXCEPT_______.
Caraccountfor______thegreenhousegasesintheUS.
随机试题
A.首乌藤B.酸枣仁C.远志D.珍珠心神不宁兼目赤翳障,首选
国有、集体企业出售,被出售企业法人予以注销,并且买受人妥善安置原企业_____以上职工的,对其承受所购企业的土地、房屋权属,减半征收契税。()
婴儿少尿的标准是每日尿量少于()
甲公司是横跨多个行业经营的大型企业,总部设在中国上海市,并在美国纽约证券交易所上市。为认真贯彻落实财政部等五部委发布的《企业内部控制基本规范》及《企业内部控制配套指引》的要求,甲公司于2014年末召开内部控制体系建设专题会议,部署实施企业内部控制体系建设。
关于零基预算法,下列说法不正确的是()。
在我国,按照普通程序,法律要经过全国人大或全国人大常委会的过半数通过。这里的“过半数”是按()。(2009年济南市安置军队转业干部考试真题)
以A表示事件“甲种产品畅销,乙种产品滞销”,则其对立事件为()
假设随机变量X1,X2,…相互独立且服从同参数A的泊松分布,则下面随机变量序列中不满足切比雪夫大数定律条件的是
Healthimpliesmorethanphysicalfitness.Italsoimpliesmentalandemotionalwell-being.Anangry,frustrated,emotionally【C1
查找教师表中教师最高的工资值,下列SQL语句正确的是
最新回复
(
0
)